The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
The conversation humorously critiques the lack of common sense in discussions about hair loss treatments like finasteride, minoxidil, and biotin, while also highlighting the repetitive nature of advice in the community. It suggests that joke posts keep the community engaging, despite some users taking absurd claims seriously.
A user shared 3-month progress pictures using 1mg finasteride daily, reporting no side effects and planning to add oral minoxidil. Replies praised the results and questioned the need to add minoxidil.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
The user experienced significant hair improvement after switching from topical to oral treatments, using finasteride, minoxidil, and biotin. They reported no major side effects, except for slightly thicker hair on their hands.
Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.
The user saw some hair regrowth with topical finasteride but is switching to oral finasteride due to supply issues. They also tried needling and minoxidil.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
OP is using oral 1mg finasteride, topical minoxidil, and microneedling twice a month at .75mm to regrow hair. They shared progress pictures over two months, noting they were bald for years before starting treatment.